Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

The Global Drug Discovery Market to Showcase Growth at a CAGR of ~8% by 2027 | DelveInsight

Published

on

<!– Name:DistributionId Value:8792326 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:8e281e1f-a812-4ee7-8649-48ab309aa409 –>

New York, USA, March 21, 2023 (GLOBE NEWSWIRE) — The Global Drug Discovery Market to Showcase Growth at a CAGR of ~8% by 2027 | DelveInsight

The drug discovery market is expanding rapidly, owing primarily to the rising prevalence of chronic and rare diseases such as cancer, cardiovascular disease, diabetes, and sickle cell anemia, among others. Furthermore, increasing R&D expenditure and investments in the development of novel drug molecules, the presence of a robust number of pipeline products across the globe, a surging number of biologics and generic drugs, increasing new drug launches and approvals, the presence of key players and CRO’s in the market, and others will create a demand for drug discovery services in the market.

DelveInsight’s Drug Discovery Market Insights report provides the current and forecast market analysis, individual leading drug discovery companies’ market shares, challenges, drug discovery market drivers, barriers, and trends, and key drug discovery companies in the market.

Key Takeaways from the Drug Discovery Market Report

  • As per DelveInsight estimates, North America is anticipated to dominate the global drug discovery market during the forecast period. 
  • Notable drug discovery companies such as Existencia, Evotec, Curia Global, Inc., Laboratory Corporation of America Holdings., GenScript, Thermo Fisher Scientific Inc., Charles River Laboratories., WuXi AppTec, Dalton Pharma Services, Oncodesign, Jubilant Biosys Ltd., IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Pharmaron, Domainex, TCG Lifesciences Pvt. Ltd., Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), and several others are currently operating in the drug discovery market.
  • In March 2023, Iktos, a company that specializes in artificial intelligence for new drug discovery, announced the completion of a € 15.5 million Series A financing led by new investors M Ventures and Debiopharm Innovation Fund, with participation from Omnes Capital.
  • In February 2023, Lantern Pharma Inc., a clinical stage biopharmaceutical company that uses its proprietary RADR® artificial intelligence (“AI”) and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced product roadmap expansions and updates that will enhance its oncology drug discovery capabilities.
  • In December 2022, TG Therapeutics, Inc. got approval for BRIUMVI™ (ublituximab-xiiy) injection, a new drug molecule for treating relapsing forms of multiple sclerosis.
  • In September 2022, CytoReason entered a multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development program. 
  • In January 2022, Evotec and Boehringer Ingelheim formed a target, and drug development collaboration focused on iPSC-based disease modeling for ophthalmologic illnesses.

To read more about the latest highlights related to the drug discovery market, get a snapshot of the key highlights entailed in the Global Drug Discovery Market Report

Drug Discovery Overview

Drug discovery is the process of discovering novel candidate pharmaceuticals in the fields of medicine, biotechnology, and pharmacology. Historically, medications were discovered by identifying the active ingredient in traditional cures or by chance, as was the case with penicillin. Chemical libraries of synthesized small molecules, natural products, or extracts were screened in intact cells or complete organisms to identify compounds with a desirable therapeutic effect in a method known as classical pharmacology. After the human genome was sequenced, which enabled quick cloning and synthesis of large quantities of purified proteins, it became common practice to use high throughput screening of sizable compound libraries against isolated biological targets that are hypothesized to be disease-modifying, a process known as reverse pharmacology.

Drug Discovery Market Insights

North America dominated global drug discovery in 2021 and will continue to do so throughout the forecast period of 2022–2027. This can be attributed to the region’s increasing demand for drug discovery among patients due to the region’s increasing prevalence of various chronic diseases. Furthermore, various strategic steps by key players are expected to boost the drug discovery market in North America. For example, CytoReason entered a multi-year partnership with Pfizer in September 2022 to use CytoReason’s artificial intelligence technology in Pfizer’s drug development program. Collaborations between key market players in the United States to implement AI technology in drug discovery are expected to drive the growth of the drug discovery market in this region.

Moreover, biosimilars have great potential in the region because they are more expensive, more effective, and have fewer side effects. TG Therapeutics, Inc. received approval in December 2022 for BRIUMVITM (ublituximab-xiiy) injection, a new drug molecule used to treat relapsing forms of multiple sclerosis. Many other new drug entities, such as lenacapavir, adagrasib, olutasidenib, and others, were approved by the US FDA in 2022.

To know more about why North America is leading the market growth in the drug discovery market, get a snapshot of the Drug Discovery Market Outlook 

Drug Discovery Market Dynamics

The high capital investment in the drug discovery and development process may be one of the key factors influencing the growth of the drug discovery market. Following the conventional method of drug discovery and development consumes 12-14 years before a final product reaches the market for end users. Another factor driving the drug discovery market is the increasing prevalence of chronic diseases such as cancer, cardiovascular disease, diabetes, hemoglobin diseases, and rare diseases. Moreover, the rapid growth of the pharmaceutical industry is also expected to drive the drug discovery market in the coming years. The biopharmaceutical industry is rapidly expanding due to increased government and corporate investments in developing new medicines to treat chronic diseases. Furthermore, favorable government regulations, combined with the active role of authorities such as the FDA and EMA, are fueling drug discovery market growth.

However, large capital investments with low profit margins, stringent government regulations approval process, and other factors may slow the growth of the drug discovery market.

Additionally, during the COVID-19 pandemic, the drug discovery market was positively impacted. During the COVID-19 pandemic, almost all countries’ healthcare systems invested heavily in research and development to combat the virus. In clinical trials, various potential compounds from the CHEMBL, ZINC, and FDA-approved drugs and molecules were screened. In addition, research teams around the world were identifying new molecules or drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and halt viral replication. As a result of the increased demand for research and development for COVID-19 drugs and vaccines, the demand for the drug discovery market increased significantly, propelling the drug discovery market growth.

Get a sneak peek at the drug discovery market dynamics @ Drug Discovery Market Dynamics Analysis

Report Metrics Details
Coverage Global
Study Period 2019–2027
Base Year 2021
Drug Discovery Market CAGR ~8%
Projected Drug Discovery Market Size by 2027 USD 97 Billion
Key Drug Discovery Companies Existencia, Evotec, Curia Global, Inc., Laboratory Corporation of America Holdings., GenScript, Thermo Fisher Scientific Inc., Charles River Laboratories., WuXi AppTec, Dalton Pharma Services, Oncodesign, Jubilant Biosys Ltd., IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Pharmaron, Domainex, TCG Lifesciences Pvt. Ltd., Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), among others

Drug Discovery Market Assessment

  • Drug Discovery Market Segmentation
    • Market Segmentation By  Workflow: Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, and Others
    • Market Segmentation By  Drug Type: Small Molecule Drugs and Biologic Drugs
    • Market Segmentation By Technology: High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, and Others
    • Market Segmentation By Service Provider: Pharmaceutical Companies, Contract Research Organizations (CROS), and Others
    • Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
  • Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the drug discovery market are set to emerge as the trendsetter explore @ Drug Discovery Companies 

Table of Contents 

1 Report Introduction
2 Executive summary
3 Regulatory and Patent Analysis
4 Key Factors Analysis
5 Porter’s Five Forces Analysis
6 COVID-19 Impact Analysis on Drug Discovery Market
7 Drug Discovery Market Layout
8 Global Company Share Analysis – Key 3-5 Companies
9 Drug Discovery Market Company and Product Profiles
10 Project Approach
11 About DelveInsight

Interested in knowing the drug discovery market by 2027? Click to get a snapshot of the Drug Discovery Market Trends

Related Reports

AI in Drug Discovery Market

AI in Drug Discovery Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug discovery companies including IBM Corporation, NuMedii Inc, Deep Genomics, NVIDIA Corporation., Atomwise Inc., Cloud Pharmaceuticals, Inc, among others.

Drug Delivery Devices Market

Drug Delivery Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key drug delivery devices companies, including Pfizer, Inc, Johnson & Johnson Services, Inc, F. Hoffmann-La Roche, Ltd, Novartis, among others.

Novel Drug Delivery Devices Market

Novel Drug Delivery Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key novel drug delivery devices companies, including Pfizer, Johnson & Johnson Services, Roche, Novartis, among others.

Drug Infusion Systems Market

Drug Infusion Systems Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key drug infusion systems companies, including B. Braun Melsungen AG, Medtronic, BD, PROMECON GmbH, arcomed ag, Fresenius Kabi AG, among others.

Transdermal Drug Delivery Devices Market

Transdermal Drug Delivery Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key transdermal drug delivery devices companies, including Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Erste Asset Management Selects Clearwater Analytics to Help Support Business Growth

Published

on

erste-asset-management-selects-clearwater-analytics-to-help-support-business-growth

Clearwater Will Aggregate Multi-Asset Client Investment Data, Help Increase Asset Flows and Strengthen Client Service
BOISE, Idaho and VIENNA, May 14, 2024 /PRNewswire/ — Clearwater Analytics (NYSE: CWAN), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that Erste Asset Management GmbH, part of Erste Group Bank AG, has joined its community of European buy-side clients. Erste Asset Management (Erste AM) is one of the leading asset managers in Central and Eastern Europe managing €81.4 billion in assets for a broad client base including pension plans.

Erste AM has chosen Clearwater’s cloud-native client reporting platform following a rigorous RFP selection process. By leveraging the Clearwater PRISM platform, Erste AM will be able to provide highly customized digital client experiences. Additionally, clients will have the ability to configure insights and analytics as well as access data in a self-service manner, allowing for quick reporting changes when needed.
“We are dedicated to surpassing customer expectations and providing exceptional client reporting across all channels,” said Winfried Buchbauer, COO and Board Member of Erste Asset Management. “Clearwater stood out from other solutions due to its flexible and cloud-native client reporting solution. Clearwater PRISM will allow us to easily tailor reports to our clients’ needs. With a comprehensive view of data, insights, and relevant analytics, our team is empowered to help differentiate our offerings in the market.”
“We understand the importance of this project to Erste Asset Management and are appreciative of the trust they have placed in us to deliver for their employees, stakeholders and clients,” expressed Keith Viverito, General Manager of EMEA and APAC at Clearwater Analytics. “This partnership underscores the best-in-class client reporting capabilities of our Clearwater PRISM platform. By bridging a critical industry gap, PRISM empowers firms like Erste Asset Management to centralize reporting across multiple systems, simplifying and modernizing the operating model and unlocking opportunities for differentiation and significantly enhanced client reporting experiences.”
Clearwater PRISM is a leading data management and client reporting platform for firms that want a comprehensive view of their portfolios across multiple platforms and all asset types. Leading organizations are making Clearwater PRISM an integral part of their investment data management strategy. To learn more about Clearwater PRISM, speak to an expert today.
About Erste Asset Management
Erste Asset Management (Erste AM) coordinates, and is responsible for, all asset management activities within Erste Group Bank AG. At our offices in Austria, Croatia, Czech Republic, Germany, Hungary, Romania and Slovakia, we manage assets of EUR 81.4 bn (31.03.2024).
About Clearwater Analytics
Clearwater Analytics (NYSE: CWAN), a global, industry-leading SaaS solution, automates the entire investment lifecycle. With a single instance, multi-tenant architecture, Clearwater offers award-winning investment portfolio planning, performance reporting, data aggregation, reconciliation, accounting, compliance, risk, and order management. Each day, leading insurers, asset managers, corporations, and governments use Clearwater’s trusted data to drive efficient, scalable investing on more than $7.3 trillion in assets spanning traditional and alternative asset types. Additional information about Clearwater can be found at clearwateranalytics.com.
Logo – https://mma.prnewswire.com/media/1502063/4701883/Clearwater_Analytics_v3_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/erste-asset-management-selects-clearwater-analytics-to-help-support-business-growth-302143784.html

Continue Reading

Artificial Intelligence

ASSA ABLOY hosts its Capital Markets Day

Published

on

assa-abloy-hosts-its-capital-markets-day

STOCKHOLM, May 14, 2024 /PRNewswire/ — Today, Tuesday 14 May, starting at 13:30 CEST, ASSA ABLOY hosts its Capital Markets Day in Prague, Czech Republic, where Nico Delvaux, President & CEO and Erik Pieder, CFO, will provide an update on ASSA ABLOY’s strategy and direction. This will include an overview of strategic activities that ASSA ABLOY is working on to continue to grow the business profitably. The financial targets of an EBIT-margin of 16-17% and an annual sales growth of 10% over a business cycle are re-confirmed. No detailed outlook statement will be made.

The CMD will also include an overview of Global Technologies’ business unit Global Solutions, the recently acquired Hardware and Home Improvement (HHI) as well as an overview of the Entrance Systems division.  
Speakers during the day are Stephanie Ordan, Head of Global Solutions, Tim Goff, Head of Americas Residential (HHI) and Massimo Grassi, Head of Entrance Systems.
The CMD will continue tomorrow with a site visit at our cylinder factory in Rychnov, Czech Republic.
Some of the material from the CMD will be made available on our website www.assaabloy.com/group/en/investors a couple of days after the event.
For more information, please contact:Carl Wahlberg, Investor Relations OfficerPhone: +46 (0) 733 27 27 [email protected]
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/assa-abloy/r/assa-abloy-hosts-its-capital-markets-day,c3972444
 

View original content:https://www.prnewswire.co.uk/news-releases/assa-abloy-hosts-its-capital-markets-day-302144477.html

Continue Reading

Artificial Intelligence

HTX Ventures Invests in ChainML, Developer of Theoriq AI Agent Protocol, to Support Decentralized AI Agent Protocol Development

Published

on

htx-ventures-invests-in-chainml,-developer-of-theoriq-ai-agent-protocol,-to-support-decentralized-ai-agent-protocol-development

SINGAPORE, May 14, 2024 /PRNewswire/ — With a commitment to broadening the reach and usability of blockchain technologies, HTX Ventures, the global investment arm of the cryptocurrency exchange HTX, has announced a strategic investment in ChainML, a Silicon Valley-based AI and ML development and research lab that recently unveiled its groundbreaking Agentic Base Layer, Theoriq.

ChainML recently raised $6.2 million during its Super Seed funding round, led by Hack VC. The funding underscores the confidence and excitement surrounding ChainML’s vision to seamlessly integrate AI into the decentralized world of blockchain and revolutionize the AI landscape. By providing a platform like Theoriq for limitless AI innovation, built on the principles of composability, extensibility, and community-driven governance, ChainML promises to offer an unmatched ecosystem for deploying sophisticated AI agents that leverage Web3 technology to ensure transparency, security, and efficiency.
Theoriq’s axioms, based on principles of social evolution and implemented with blockchain, lay the foundation for continuously improving, community-governed AI systems.
Key features include:
Agentic Primities: Fundamental elements in the ecosystem that facilitate autonomous interaction, embodying roles, behaviors, and functions that contribute directly to an agent’s capacity to operate independently within its environment.Modular Composability: Allowing developers to craft tailored AI solutions that can combine and be recombined to create sophisticated systems to evolve and adapt over time.Community Permissioned Governance: Ensuring that decision-making authority is vested in a diverse group of community stakeholders who actively contribute to and provide feedback on the quality of AI agents, ensuring that the technology aligns with collective goals and values.Edward, Managing Partner at HTX Ventures, said “ChainML’s Theoriq is an innovative platform that provides an actionable solution for AI agents to interact interchangeably, packed with more autonomy and capability. The platform paves the way for the future of AI, we are excited to be part of this journey.”
“Today marks a pivotal moment for ChainML and for the broader AI and Web3 communities,” said Ron Bodkin, Co-founder & CEO of ChainML. “With Theoriq, we’re not just launching a product—we’re spearheading a movement towards a transparent, community-governed AI ecosystem. HTX Ventures’ support will be instrumental as we unlock new potentials for AI integration within the decentralized space.”
HTX Ventures is excited to support innovative projects like ChainML, which combine AI development with blockchain to explore new synergies. Users can interact with the Theoriq testnet this summer by joining the waitlist.
Contact DetailsMichael [email protected]
Company Websitehttps://www.htx.com/en-us/ventures
Photo – https://mma.prnewswire.com/media/2411969/image_838145_9931602.jpgLogo – https://mma.prnewswire.com/media/2391903/image_ID__Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/htx-ventures-invests-in-chainml-developer-of-theoriq-ai-agent-protocol-to-support-decentralized-ai-agent-protocol-development-302144332.html

Continue Reading

Trending